Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05000294
Title Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University of Florida

neuroendocrine tumor

breast cancer

vulva cancer

ovarian cancer

pancreatic adenocarcinoma


prostate cancer

gallbladder cancer

bile duct cancer


Atezolizumab + Tivozanib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST